Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Oncology Announces $4.1M Direct Offering

NEW YORK – Predictive Oncology said Friday that it has reached agreements with investors for a direct offering of more than 3.4 million shares at $1.20 per share, for gross proceeds of approximately $4.1 million.

The firm also has agreed to issue investors slightly more than 1.7 million warrants at $1.37 per share. These warrants will expire 5.5 years from issuance.

This is the Eagan, Minnesota-based company's second such move this week. A $2.2 million offering of 2.2 million shares at $1 per share closed Thursday. That offering also included 1.1 million warrants at $1 per share. 

As with the earlier offering, Predictive Oncology said that it would use the proceeds for working capital.

Once again, H.C. Wainwright is the exclusive placement agent for this offering, which is priced at-market, per Nasdaq rules. Predictive Oncology said that it expects the offering to close on or about Jan. 26.

The firm operates through three subsidiaries: Helomics, which provides tumor-analysis services for treatment personalization and new drug development; TumorGenesis, which is developing patient-derived tumor models for precision drug testing; and Skyline Medical, which markets a US Food and Drug Administration-approved system for automated medical fluid disposal. 

In Friday morning trading on the Nasdaq, Predictive Oncology stock was at $1.20, down more than 12 percent from the previous day's close at $1.37.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.